We do not publish a verdict for Morgan Stanley (MS) and Nomura Holdings Inc ADR (NMR) is undervalued.
We publish an intrinsic value for NMR but not for MS, so the two cannot be ranked on price.
Values as of the 22 Sept 2026 close.
Discounting its cash flows would put the shares at $1019.95: 5 times the price of $200.18. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
Leak Score 53/100 on 9 of 12 signals
Discounting its cash flows at 5.7% values the shares at $22.48; the price of $9.96 is 56% below that value, and 88% of that value comes from beyond year five.
Leak Score 41/100 on 3 of 12 signals
| Metric | MS | NMR |
|---|---|---|
| Verdict | No reliable verdict | Undervalued |
| Price | $200.18 | $9.96 |
| Intrinsic value | — | $22.48 |
| Margin of safety | — | +56% |
| Leak Score | 53/100 (9/12) | 41/100 (3/12) |
| Market cap | $314.4B | $29.1B |
| Revenue growth, 5 years | 17.8% | 15.7% |
| Operating margin | 20.1% | 11.9% |
| Net margin | 15.2% | 8.1% |
| Return on equity | 17.9% | 10.9% |
| Debt to equity | 4.69 | 10.19 |
| P/E | 16.2x | 11.6x |
| Forward P/E | 14.6x | 10.4x |
| P/B | 3.0x | 1.2x |
| Dividend yield | 2.1% | 3.9% |